Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer

Naito, Tateaki; Tanaka, Fumihiro; Ono, Akira; Yoneda, Kazue; Takahashi, Toshiaki; Murakami, Haruyasu; Nakamura, Yukiko; Tsuya, Asuka; Kenmotsu, Hirotsugu; Shukuya, Takehito; Kaira, Kyoichi; Koh, Yasuhiro; Endo, Masahiro; Hasegawa, Seiki; Yamamoto, Nobuyuki

doi:10.1097/jto.0b013e31823f125d

Cited by 162 publications

(127 citation statements)

References 34 publications

(49 reference statements)

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…For example, in SCLC the total numbers of CTCs were significantly decreased following a single dose of chemotherapy (166,167). Similar results were observed in patients with NSCLC (5,(168)(169)(170).…”

Section: Treatment Response and Mechanisms Of Resistancesupporting

confidence: 74%

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Mohan¹,

Chemi²,

Brady³

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Section: Treatment Response and Mechanisms Of Resistancesupporting

confidence: 74%

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Mohan¹,

Chemi²,

Brady³

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

“…Based on this view, only CSCs are able to survive the difficulties of metastatic development. For this reason, clinical reports evaluating CTCs have provided contradictory results with various studies indicating that CTC detection may be associated with poor prognosis (38,39) whereas others have failed to show such an association (40).…”

Section: Discussionmentioning

confidence: 88%

Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer

et al. 2013

View full text Add to dashboard Cite

Abstract. The epithelial-mesenchymal transition (EMT) is a program involved in embryonic development that is often activated during cancer invasion and metastasis. CD133 is the main marker identifying cancer stem cells (CSCs) in lung cancer. Circulating tumor cells (CTCs) are demonstrated to be useful as a biomarker for the diagnosis and treatment of cancer. The aim of this study was to correlate EMT, CSCs and CTCs with patient prognosis to verify whether they can contribute to better stratification of lung cancer patients at risk for recurrent and metastatic disease. Pulmonary venous blood was drawn after major pulmonary surgery in 45 patients with resectable non-small cell lung cancer (NSCLC) in order to identify CTCs. For the same patients, we also constructed prognostic lung tissue microarrays (TMA) for CD133 and c-kit and evaluated CSC and EMT markers using flow cytometry. Cytokeratin-positive cells were detectable in 11 (23.9%) cases. c-kit expression was heterogeneous in prognostic TMAs while CD133 expression was low or absent which was also confirmed by flow cytometry and RT-PCR. Flow cytometric analysis showed that the mean percentage of cells with CD133 expression was 1.6%. CD90 and CD326 markers were co-expressed with a mean percentage of 10.41%. When CD133 and CD90/CD326 expression was correlated with follow-up, CD133 showed a higher correlation with deceased patients when compared with CD90/ CD326 co-expression (32.5 vs. 9.5%). CD133 expression demonstrated a strong significant association with patients exhibiting progressive disease when compared to CD90/ CD326 expression (15 vs. 7.1%). CD133 may be significantly associated with invasion and metastatic spread of NSCLC. The co-expression of CD90, CD326 and CD133 has definite prognostic value in patients with NSCLC.

show abstract

“…Therefore, these cancer cells have to be enriched by various methods for further analysis. However, SCLC patients can exhibit extreme numbers of CTCs which have prognostic significance and correlate with responses to chemotherapy (58)(59)(60). For example, CTCs were identified in 90% (54/60) of patients at baseline, with CTC reaching numbers of up to 24,281/7.5 mL blood as determined using the CellSearch ® system (61).…”

Section: Sclc and Ctcsmentioning

confidence: 99%

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Hamilton¹,

Rath²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

CTCs. SCLC has an unfavorable prognosis due to rapid dissemination and early chemoresistant relapses. SCLC CTCs recruit macrophages and elicit secretion of various cytokines and the six CTC lines expresschitinase-3-like-1 (CHI3L1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP9) in abundance. CHI3L1 is cytokine/growth factor expressed in inflammation and cancer and found to be correlated to metastasis and a dismal prognosis. In conclusion, SCLC CTCs have acquired the essential means for aggressiveness and invasion in a tumor microenvironment specifically shaped by macrophages and inflammation.

show abstract

Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer

Abstract: CTCs were highly detectable in SCLC, and higher CTC levels were strongly associated with worse survival. Consistently favorable CTC levels were associated with favorable outcomes.

Cited by 162 publications

References 34 publications

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Contact Info

Product

Resources

About